Not independent
Tenure on this board
4.2 yrs
Also a director at
Acadian Asset Management Inc (AAMI)Bausch & Lomb Corp (BLCO)
Meeting calendar
BHC · Special meeting · Tuesday, October 7, 2025
Bausch Health Companies Inc
13 nominees · 1 ballot item.
Ratification, confirmation and approval of the Amended and Restated Shareholder Rights Plan.
Market cap
$2.4B
1Y TSR
-19.4%
Board grade
C
Record date
Aug 18, 2025
Filing
DEF 14A
Meeting concluded · Oct 7, 2025
Follow how the vote landed and what changed on Bausch Health Companies Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot1
- 1
Ratification, Confirmation and Approval of the Rights Agreement
ManagementBoard: FORProposal to ratify and approve the Amended and Restated Shareholder Rights Plan adopted by the Board to deter unsolicited take-over bids and to promote fair treatment of shareholders; the Plan provides for Rights and a Permitted Bid framework.
Director elections
Nominees on the ballot13
Not independent
Tenure on this board
4.3 yrs
Also a director at
Bausch & Lomb Corp (BLCO)
Not independent
Tenure on this board
New nominee
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
2.3 yrs
Also a director at
Tetra Technologies Inc (TTI)Mueller Water Products Inc (MWA)
Independent
Tenure on this board
0.9 yrs
Independent
Tenure on this board
10.1 yrs
Also a director at
Bausch & Lomb Corp (BLCO)
Independent
Tenure on this board
2.3 yrs
Also a director at
Pacira Biosciences Inc (PCRX)
Independent
Tenure on this board
1.1 yrs
Independent
Tenure on this board
New nominee
Independent
Tenure on this board
3.9 yrs
Also a director at
Sana Biotechnology Inc (SANA)International Flavors & Fragrances Inc (IFF)
Independent
Tenure on this board
18.0 yrs
Independent
Tenure on this board
10.2 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | MFN Partners Management, LP | 1.6% | 6,000,000 | $30M |
| 2 | SG Americas Securities, LLC | 1.5% | 5,535,771 | $27M |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 4,764,873 | $33M |
| 4 | NORGES BANK | 0.9% | 3,431,117 | $17M |
| 5 | DIMENSIONAL FUND ADVISORS LP | 0.8% | 2,842,240 | $14M |
| 6 | PRIVATE MANAGEMENT GROUP INC | 0.5% | 1,683,837 | $8M |
| 7 | TD ASSET MANAGEMENT INC | 0.3% | 938,710 | $5M |
| 8 | BANK OF MONTREAL /CAN/ | 0.2% | 892,927 | $4M |
| 9 | JPMORGAN CHASE CO | 0.2% | 878,836 | $4M |
| 10 | GAMCO INVESTORS, INC. ET AL | 0.2% | 707,256 | $3M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bausch Health Companies Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Ataibeckley IncATAI
Special meeting·Sep 8, 2026·$2.7B
Kestra Medical Technologies LtdKMTS
Annual meeting·Sep 9, 2026·$1.6B
Replimune Group IncREPL
Annual meeting·Sep 15, 2026·$1.3B
Artiva Biotherapeutics IncARTV
Annual meeting·Sep 8, 2026·$560M
Ocugen IncOCGN
Special meeting·Sep 21, 2026·$458M
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.4B
Reference
Frequently asked questions
- When is the Bausch Health Companies Inc 2025 special meeting?
- Bausch Health Companies Inc (BHC) holds its 2025 special shareholder meeting on Tuesday, October 7, 2025.
- What is the record date for the Bausch Health Companies Inc 2025 meeting?
- The record date for the Bausch Health Companies Inc 2025 meeting is Monday, August 18, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bausch Health Companies Inc's 2025 meeting?
- The board is presenting 13 director nominees at the Bausch Health Companies Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bausch Health Companies Inc 2025 meeting?
- Shareholders will vote on 1 proposal at the Bausch Health Companies Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.